Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Trillium Therapeutics Inc. (TRIL)

18.44   0 (0%) 08-08 00:49
Open: 17.92 Pre. Close: 18.44
High: 18.49 Low: 17.83
Volume: 26,174,709 Market Cap: 1,936(M)
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -

Technical analysis

as of: 2022-01-21 4:31:06 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 21.59     One year: 25.22
Support: Support1: 18.08    Support2: 17.82
Resistance: Resistance1: 18.48    Resistance2: 21.59
Pivot: 18.44
Moving Average: MA(5): 18.44     MA(20): 18.44
MA(100): 17.99     MA(250): 13.12
MACD: MACD(12,26): 0.02     Signal(9): 0.03
Stochastic oscillator: %K(14,3): 92.42     %D(3): 92.42
RSI: RSI(14): 73.35
52-week: High: 18.48  Low: 5.8
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Headline News

Sun, 07 Aug 2022
Japan's Jan.-June current account surplus shrinks to 3.51 tril. yen - The Mainichi - The Mainichi

Thu, 04 Aug 2022
Survey: 260 tril. yen needed for Japan's zero-carbon push - NHK WORLD

Thu, 04 Aug 2022
Toyota raises net profit forecast to 2.36 tril. on weaker yen -

Wed, 03 Aug 2022
Japan to seek record 5.5 tril. yen defense budget to beef up tech - Kyodo News Plus

Thu, 28 Jul 2022
Tax revenue up 36.5 tril. won in H1 amid economic recovery - 코리아타임스

Thu, 28 Jul 2022
Malaysia's exports at record high, total trade surpasses RM2 tril in 2021 - Free Malaysia Today

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 105 (M)
Shares Float 87 (M)
% Held by Insiders 5.4 (%)
% Held by Institutions 81.8 (%)
Shares Short 2,310 (K)
Shares Short P.Month 2,810 (K)

Stock Financials

EPS -0.5
EPS Est Next Qtl -0.96
EPS Est This Year -4.14
EPS Est Next Year -2.75
Book Value (p.s.) 2.32
Profit Margin (%) 0
Operating Margin (%) -118642
Return on Assets (ttm) -15.61
Return on Equity (ttm) -29.91
Qtrly Rev. Growth -91.31
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.49
Qtrly Earnings Growth 0
Operating Cash Flow -38 (M)
Levered Free Cash Flow -19 (M)

Stock Valuations

PE Ratio -36.89
PEG Ratio 0
Price to Book value 7.91
Price to Sales 45027.9
Price to Cash Flow -0.01

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.